about
Serum and cerebrospinal fluid immune mediators in children with autistic disorder: a longitudinal studyModerators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability.Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggressionSerum ferritin and amphetamine response in youth with attention-deficit/hyperactivity disorderLongitudinal study of symptom severity and language in minimally verbal children with autismAggression in children with autism spectrum disorders and a clinic-referred comparison group.Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression.Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom responseComorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorderThe treatment of severe child aggression (TOSCA) study: Design challenges.Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders.The ADOS calibrated severity score: relationship to phenotypic variables and stability over time.Evaluation of Periodic Limb Movements in Sleep and Iron Status in Children With Autism.Factor Validity of a Proactive and Reactive Aggression Rating ScaleState-Dependent Differences in Functional Connectivity in Young Children With Autism Spectrum Disorder.Cohort study of neurocognitive functioning and adaptive behaviour in children and adolescents with Niemann-Pick Disease type C1.Confirmation of the Factor Structure and Measurement Invariance of the Children's Scale of Hostility and Aggression: Reactive/Proactive in Clinic-Referred Children With and Without Autism Spectrum Disorder.Development, behavior, and biomarker characterization of Smith-Lemli-Opitz syndrome: an update.Pharmacotherapy for the core symptoms in autistic disorder: current status of the researchMeasurement of nonverbal IQ in autism spectrum disorder: scores in young adulthood compared to early childhood.Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial.Cortical thickness change in autism during early childhood.CSF concentrations of 5-methyltetrahydrofolate in a cohort of young children with autismDietary adequacy of children with autism compared with controls and the impact of restricted dietPredictors and moderators of parent training efficacy in a sample of children with autism spectrum disorders and serious behavioral problems.What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder.Aripiprazole for the treatment of irritability associated with autism.Demystifying moderators and mediators in intellectual and developmental disabilities research: a primer and review of the literature.Pediatric Acute-Onset Neuropsychiatric Syndrome Response to Oral Corticosteroid Bursts: An Observational Study of Patients in an Academic Community-Based PANS Clinic.Effect of Early and Prophylactic Nonsteroidal Anti-Inflammatory Drugs on Flare Duration in Pediatric Acute-Onset Neuropsychiatric Syndrome: An Observational Study of Patients Followed by an Academic Community-Based Pediatric Acute-Onset NeuropsychiaRandomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections.Concurrent validity of the differential ability scales, second edition with the Mullen Scales of Early Learning in young children with and without neurodevelopmental disorders.Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation.Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory.Identification of Developmental and Behavioral Markers Associated With Genetic Abnormalities in Autism Spectrum Disorder.Riluzole Serum Concentration in Pediatric Patients Treated for Obsessive-Compulsive Disorder.Psychometric properties of the Children's Scale of Hostility and Aggression: Reactive/Proactive (C-SHARP).Describing Function in ASD: Using the DSM-5 and Other Methods to Improve Precision.Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings.
P50
Q28397818-DD6580EA-5E62-4AC3-A5FA-4AABFBE6EDB1Q33832125-C6D1EC36-8DEF-44A7-8A91-0C58866C01B1Q34094034-FFD55EE2-2826-4B9D-B866-3D697CD0B0A8Q34413192-7ADF1D27-BCEE-4D20-BDE3-46B68259344FQ34426321-CF90759C-5346-41C2-AE20-3FF7F685AD16Q35091413-BE38D0DE-198F-46BB-B24C-0536E93B8633Q35483556-297157D5-D447-427B-B0C2-508E60FE4115Q35485907-3CC0A23F-78C9-4EE2-A51C-053E33879BA5Q35486056-592F3AD7-CB00-44A8-9433-7F1EAFDD70C0Q35595839-40259CF2-4611-4A33-9623-62AE70C2E565Q36158842-4080CB6D-DC09-4045-8FE5-CE5AAFADC6AAQ36173788-9033F243-63C4-40E7-8E01-F4D6EAA01A32Q36175044-B5B91FC8-FFE1-4063-849B-6D2C9EEEDDA8Q36197630-8A17690E-4F31-4FDA-8DCC-267FDC2CE2AAQ36437610-FDBA4501-8BBB-4397-BDFB-E277F279036DQ36599156-FBD222A6-9525-4A79-8D73-75E0E2B2C4ADQ36654469-03D75AF4-A7AF-4806-98B7-62F11BCDE991Q36769336-4A5B720B-35E3-45A5-BAFA-06E5A70CDA26Q36784208-031A1EE5-C2F9-43FF-898D-8D76EFEBF622Q36925925-01251A66-CCFD-4CC1-BBA3-4B81FA2100BDQ36949869-C9E65025-DD22-40C2-8BDB-6752609392E9Q36999180-23DFBAB5-14DA-4950-B918-9E5C14512972Q37008938-8779433A-99DA-4314-A5E9-C9D6670286AAQ37284943-794AC2B7-B5BE-44D7-83BF-399D68652D44Q37547908-C0C667A8-0504-414E-A51D-C4D11E041391Q37699333-6FC15FA7-AE44-4F5F-8C82-16C3C768C88AQ37705750-70D126ED-758C-42CC-AE91-C6B47569DF98Q37835845-EBB8FEFA-F1C6-4CAD-A93D-459895F917FBQ37979312-0D9DB5F8-8EC6-4950-BA08-9B2B46DA5463Q38675984-C6BA31E9-0F9D-43AE-BE26-F8FC6E963225Q38684263-D830C936-F320-483A-B434-EE9AEE047CE7Q38818149-970C1E20-8D51-4587-A579-6C91B93AD343Q39022672-8A20F575-CB77-4D8D-B3EA-B3C480EBAECCQ39623619-5AE4F0A0-EAFF-44BD-A4E6-0F0050910246Q39652199-47B936B9-7B90-465E-A761-B25A7B7DFE3BQ40311138-BE05F270-CE42-4781-8C97-8F18A2869A33Q42697702-960D4E3E-D38C-4E68-BFED-44DB784C31DFQ45511250-BC24A584-09BB-4ACA-B842-F602A87978BAQ46271263-40295DF4-5446-40EB-B291-174A6B98F5A7Q47416741-542A3297-CA6F-4832-B166-194354987D72
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Cristan Farmer
@ast
Cristan Farmer
@en
Cristan Farmer
@es
Cristan Farmer
@nl
Cristan Farmer
@sl
type
label
Cristan Farmer
@ast
Cristan Farmer
@en
Cristan Farmer
@es
Cristan Farmer
@nl
Cristan Farmer
@sl
prefLabel
Cristan Farmer
@ast
Cristan Farmer
@en
Cristan Farmer
@es
Cristan Farmer
@nl
Cristan Farmer
@sl
P106
P21
P31
P496
0000-0001-6878-5199